logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 8652 352524; +7 8652 353229.

Fax
+7 8652 352524.

E-mail
medvestnik@stgmu.ru

The results of experimental studies of the use of silver nanoparticles in tuberculosis drug-resistant pathogen

[Original research] [Experimental medicine]
Andrei Vladimirovich Zakharov; Alexander Khokhlov;

A comparative evaluation of the effectiveness of various drugs in the treatment of experimental drug-resistant tuberculosis in mice was carried out. In 10 animals, isoniazid was used in the treatment at a dose of 50 mg/kg, to which MBT resistance was available. In the second group of 20 mice received a daily intramuscular injection of silver nanoparticles in doses of 12.5 to 125 μg/kg. In group 3, the isoniazid 20 animals at a dose of 50 mg/kg was used in conjunction with nanoparticles in the previously specified doses. The results showed that the use of silver nanoparticles in the treatment of experimental tuberculosis induced by drug-resistant pathogen increases the effectiveness of treatment. As the main criteria of the therapy effectiveness the survival of animals, the index of lesion and the seeding rate of the pathogen from parenchymal target organs were considered. A comparative histological assessment of the affected organs in different methods of treatment was carried out, which confirmed the effectiveness of the use of nanoparticles.

Download

References:
1. Vasilyeva I. A., Belilovsky E. M., Borisov S. E., Sterlikov S. A. Tuberkuloz s mnozhestvennoy lekarstvennoy ustoychivostyu vozbuditelya v stranakh mira i v Rossiyskoy Federatsii. Tuberkuloz i bolezni legkikh. – Tuberculosis and lung diseases. 2017;95(11):5-
16. (In Russ.). https://doi.org/10.21292/2075-1230-2017-95-11-5-17
2.Vasilyeva I. A., Belilovsky E. M., Borisov S. E., Sterlikov S. A. Globalnyye otchety
Vsemirnoy organizatsii zdravookhraneniya po tuberkulezu: formirovaniye i interpretatsiya. Tuberkuloz i bolezni legkikh. – Tuberculosis and lung diseases. 2017;95(5):7-16. (In Russ.).
https://doi.org/10.21292/2075-1230-2017-95-5-7-16
3. Borisov S. E., Ivanova D. A. Bedakvilin – novyy protivotuberkuloznyy preparat. Tuberkulez i sotsial’no znachimyye zabolevaniya. – Tuberculosis and socially significant diseases. 2014;(1-2):44-51. (In Russ.).
4. Raviglione M. K., Korobitsyn A. A. Likvidatsiya tuberkuloza – novaya strategiya VOZ v eru tseley ustoychivogo razvitiya, vklad Rossiyskoy Federatsii. Tuberkuloz i bolezni legkikh. –Tuberculosis and lung diseases. 2016;94(11):7-15. (In Russ.). https://doi.org/10.21292/2075-1230-2016-94-11-7-15
5. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update //WHO/HTM/TB/2016.04. Geneva: World Health Organization; 2016.
6. Sterlikov S. A., Nechaeva O. B., Kucheryavaya D. A., Obukhova O. V., Chebagina T. Yu. Otraslevyye i ekonomicheskiye pokazateli protivotuberkuloznoy raboty v 2015–2016 gg. Statisticheskiye materialy. M.: RIO TSNIIOIZ; 2017. (In Russ.).
7. Galkin V. B., Elenkina Zh. V., Epifantseva N. A., Zaytseva S. M., Zelenina A. Ye. [et al.]. TB/VICH v Rossiyskoy Federatsii. Epidemiologiya, osobennosti klinicheskikh proyavleniy i rezul’taty lecheniya / pod red. S. A. Sterlikova. M.: RIO TSNIIOIZ; 2017. (In Russ.)].
8. Egorova Ye. M., Kubatiyev A. A., Shvets V. I. Biologicheskiye effekty nanochastits metallov. M.: Nauka; 2014. (In Russ.).
9. Nanostruktury v biomeditsine // pod. red. K. Gonsalves, K. Khalbershtadt, K. Lorensin, L. Nair; per. s angl. M.: BINOM; 2012. (In Russ.).
10. Zakharov A. V., Khokhlov A. L., Ergeshov A. E. Nanochastitsy serebra v reshenii problemy lekarstvennoy ustoychivosti vozbuditelya. Arkhiv vnutrenney meditsiny. – Archives of internal medicine. 2017;7(3):188-199. (In Russ.). https://doi.org/10.20514/2226-6704-2017-7-3-188-199
11. Banu A., Rathod V. Biosynthesis of Monodispersed Silver Nanoparticles and their Activity against Mycobacterium tuberculosis. Journal of Nanomedicine & Biotherapeutic Discovery. 2013;3:100. http://dx.doi.org/10.4172/2155-983X.1000110
12. Alizadeh H., Salouti M., Shapouri R. Bactericidal Effect of Silver Nanoparticles on Intramacrophage Brucella abortus 544. Jundishapur Journal of Microbiology. 2014;7(3):e9039. http://dx.doi.org/10.5812/jjm.9039
13. Rajawat S., Qureshi M. S. Comparative study on bactericidal effect of silver nanoparticles, synthesized using green technology, in combination with antibiotics on Salmonella Typhi. Journal of Biomedical Nanotechnology. 2012;(3):480–485. http://dx.doi.org/10.4236/jbnb.2012.34049
14. Ursulova B. B., Husan A. O. Kliniko-bakteriologicheskoye issledovaniye effektivnosti ispolzovaniya nanochastits serebra dlya lecheniya tuberkuleza verkhnikh dykhatelnykh putey. Vestnik otorinolaringologii. – Otorhinolaryngology Herald. 2017;82(3):54-57. (In Russ.).
https://doi.org/10/17116/otorino201782354-57
15.Rukovodstvo po eksperimentalnomu (doklinicheskomu) izucheniyu novykh farmakologicheskikh veshchestv / pod obshchey redaktsiyey R. U. Khabriyeva. 2-ye izd., pererab. i dop. M.: Meditsina; 2005. (In Russ.).

Keywords: tuberculosis, drug resistance of MBT, silver nanoparticles


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy